• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用可切除胰腺导管腺癌患者治疗前 PET 和 MRI 成像特征预测肿瘤分级和生存结局。

Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma.

机构信息

Department of Diagnostic and Interventional Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Department of Visceral Surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

出版信息

Eur Radiol. 2021 Feb;31(2):992-1001. doi: 10.1007/s00330-020-07191-z. Epub 2020 Aug 26.

DOI:10.1007/s00330-020-07191-z
PMID:32851447
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7813698/
Abstract

OBJECTIVES

To perform a correlation analysis between histopathology and imaging in patients with previously untreated pancreatic ductal adenocarcinoma (PDAC) and to determine the prognostic values of clinical, histological, and imaging parameters regarding overall survival (OS), disease-specific survival (DSS), and progression-free survival (PFS).

METHODS

This single-centre study prospectively included 61 patients (32 males; median age, 68.0 years [IQR, 63.0-75.0 years]) with histologically confirmed PDAC and following surgical resection who preoperatively underwent F-FDG PET/CT and DW-MRI. On whole lesions, we measured, using a 42% SUV threshold volume of interest (VOI), the following quantitative parameters: mean and maximum standardised uptake values (SUV and SUV), total lesion glycolysis (TLG), metabolic tumour volume (MTV), mean and minimum apparent diffusion coefficient (ADC and ADC), diffusion total volume (DTV), and MTV/ADC ratio. Spearman's correlation analysis was performed to assess relationships between these markers and histopathological findings from surgical specimens (stage; grade; resection quality; and vascular, perineural, and lymphatic invasion). Kaplan-Meier and Cox hazard ratio methods were used to evaluate the impacts of imaging parameters on OS (n = 41), DSS (n = 36), and PFS (n = 41).

RESULTS

Inverse correlations between ADC and SUV (rho = - 0.34; p = 0.0071), and between SUV and ADC (rho = - 0.29; p = 0.026) were identified. ADC was inversely correlated with tumour grade (rho = - 0.40; p = 0.0015). MTV was an independent predictive factor for OS and DSS, while DTV was an independent predictive factor for PFS.

CONCLUSION

In previously untreated PDAC, ADC and SUV values are correlated. Combining PET-MRI metrics may help predict PDAC grade and patients' survival.

KEY POINTS

• Minimum apparent diffusion coefficient derived from DW-MRI inversely correlates with tumour grade in pancreatic ductal adenocarcinoma. • In pancreatic ductal adenocarcinoma, metabolic tumour volume has been confirmed as a predictive factor for patients' overall survival and disease-specific survival. • Combining PET and MRI metrics may help predict grade and patients' survival in pancreatic ductal adenocarcinoma.

摘要

目的

对未经治疗的胰腺导管腺癌(PDAC)患者的组织病理学和影像学进行相关性分析,并确定临床、组织学和影像学参数在总生存期(OS)、疾病特异性生存期(DSS)和无进展生存期(PFS)方面的预后价值。

方法

本单中心前瞻性研究纳入了 61 例经组织学证实的 PDAC 患者(32 名男性;中位年龄 68.0 岁[IQR,63.0-75.0 岁]),这些患者在接受手术切除前均接受了 F-FDG PET/CT 和 DW-MRI 检查。我们在全病灶层面上使用 42% SUV 阈值体积感兴趣区(VOI)测量以下定量参数:平均和最大标准摄取值(SUV 和 SUV)、总肿瘤糖酵解(TLG)、肿瘤代谢体积(MTV)、平均和最小表观扩散系数(ADC 和 ADC)、扩散总体积(DTV)和 MTV/ADC 比值。采用 Spearman 相关分析评估这些标志物与手术标本(分期;分级;切除质量;血管、神经周围和淋巴侵袭)组织病理学发现之间的关系。Kaplan-Meier 和 Cox 风险比方法用于评估影像学参数对 OS(n=41)、DSS(n=36)和 PFS(n=41)的影响。

结果

发现 ADC 和 SUV 之间呈负相关(rho=-0.34;p=0.0071),SUV 和 ADC 之间也呈负相关(rho=-0.29;p=0.026)。ADC 与肿瘤分级呈负相关(rho=-0.40;p=0.0015)。MTV 是 OS 和 DSS 的独立预测因素,而 DTV 是 PFS 的独立预测因素。

结论

在未经治疗的 PDAC 中,ADC 和 SUV 值呈负相关。结合 PET-MRI 指标可能有助于预测 PDAC 分级和患者的生存。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3da8/7813698/e9aed42e4122/330_2020_7191_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3da8/7813698/39cf9e3d4a9e/330_2020_7191_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3da8/7813698/771a2be64bce/330_2020_7191_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3da8/7813698/e9aed42e4122/330_2020_7191_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3da8/7813698/39cf9e3d4a9e/330_2020_7191_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3da8/7813698/771a2be64bce/330_2020_7191_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3da8/7813698/e9aed42e4122/330_2020_7191_Fig3_HTML.jpg

相似文献

1
Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma.使用可切除胰腺导管腺癌患者治疗前 PET 和 MRI 成像特征预测肿瘤分级和生存结局。
Eur Radiol. 2021 Feb;31(2):992-1001. doi: 10.1007/s00330-020-07191-z. Epub 2020 Aug 26.
2
Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.全身同步杂交 PET/MRI 评估肿瘤病变的标准化摄取值与表观扩散系数的相关性。
AJR Am J Roentgenol. 2013 Nov;201(5):1115-9. doi: 10.2214/AJR.13.11304.
3
PET/MRI in Cervical Cancer: Associations Between Imaging Biomarkers and Tumor Stage, Disease Progression, and Overall Survival.正电子发射断层显像/磁共振成像在宫颈癌中的应用:影像生物标志物与肿瘤分期、疾病进展及总生存期的相关性
J Magn Reson Imaging. 2021 Jan;53(1):305-318. doi: 10.1002/jmri.27311. Epub 2020 Aug 14.
4
Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer.联合预处理MRI和18F-FDG PET/CT参数作为宫颈癌患者的预后生物标志物
Eur J Radiol. 2014 Jul;83(7):1169-1176. doi: 10.1016/j.ejrad.2014.03.024. Epub 2014 Mar 30.
5
Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.全身 FDG PET/MR 对接受 CAR T 细胞治疗的复发/难治性大 B 细胞淋巴瘤患者进行无进展生存和总生存预测。
Cancer Imaging. 2022 Dec 27;22(1):76. doi: 10.1186/s40644-022-00513-y.
6
Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer.基于扩散加权磁共振成像的功能成像标志物与食管癌18F-氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描之间的相关性
Nucl Med Commun. 2018 Jan;39(1):60-67. doi: 10.1097/MNM.0000000000000771.
7
Prognostic value of combined MTV and ADC derived from baseline FDG PET/MRI in aggressive non-Hodgkins lymphoma.基线 FDG PET/MRI 联合 MTV 和 ADC 值对侵袭性非霍奇金淋巴瘤的预后价值。
BMC Cancer. 2022 Nov 1;22(1):1117. doi: 10.1186/s12885-022-10194-2.
8
Prognostic value of F-FDG PET/MR imaging biomarkers in oesophageal squamous cell carcinoma.氟代脱氧葡萄糖正电子发射断层扫描/磁共振成像生物标志物在食管鳞状细胞癌中的预后价值。
Eur J Radiol. 2019 Nov;120:108671. doi: 10.1016/j.ejrad.2019.108671. Epub 2019 Sep 30.
9
Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.通过整合 PET/MRI 对胰腺导管腺癌进行早期反应评估。
AJR Am J Roentgenol. 2018 Nov;211(5):1010-1019. doi: 10.2214/AJR.18.19602. Epub 2018 Jul 31.
10
Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection.通过¹⁸F-FDG PET/CT评估的代谢肿瘤负荷与血清CA19-9相关,可预测胰腺癌切除术后的预后。
Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1093-102. doi: 10.1007/s00259-014-2688-8. Epub 2014 Feb 13.

引用本文的文献

1
Toward diffusion MRI in the diagnosis and treatment of pancreatic cancer.胰腺癌诊断与治疗中的扩散磁共振成像研究进展
Med Oncol. 2025 May 28;42(7):222. doi: 10.1007/s12032-025-02759-5.
2
The minimum apparent diffusion coefficient value on preoperative magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biologically borderline resectable pancreatic cancer.可切除胰腺癌术前磁共振成像的最小表观扩散系数值:生物学上临界可切除胰腺癌的一个新的预后因素。
Surg Today. 2025 Apr 29. doi: 10.1007/s00595-025-03050-w.
3
Looking at or beyond the tumor - a systematic review and meta-analysis of quantitative imaging biomarkers predicting pancreatic cancer prognosis.

本文引用的文献

1
Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?
J Nucl Med. 2001 May;42(5):721-5.
观察肿瘤内部或外部——对预测胰腺癌预后的定量成像生物标志物的系统评价和荟萃分析
Abdom Radiol (NY). 2025 Apr 8. doi: 10.1007/s00261-025-04919-7.
4
Clinical Utility of Fluorine-Fibroblast Activation Protein Inhibitor-04 Positron Emission Tomography/Computed Tomography in the Evaluation of Pancreatic Ductal Adenocarcinoma: Comparison With Fluorine-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.氟-成纤维细胞激活蛋白抑制剂-04正电子发射断层扫描/计算机断层扫描在胰腺导管腺癌评估中的临床应用:与氟-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的比较
MedComm (2020). 2025 Mar 10;6(3):e70136. doi: 10.1002/mco2.70136. eCollection 2025 Mar.
5
Dual-energy computed tomography for predicting histological grading and survival in patients with pancreatic ductal adenocarcinoma.双能计算机断层扫描用于预测胰腺导管腺癌患者的组织学分级和生存率。
Eur Radiol. 2025 May;35(5):2818-2832. doi: 10.1007/s00330-024-11109-4. Epub 2024 Oct 16.
6
Limited Role of the Apparent Diffusion Coefficient (ADC) for Tumor Grade and Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma.表观扩散系数(ADC)在可切除胰腺导管腺癌的肿瘤分级和总生存中的作用有限。
Diagnostics (Basel). 2024 Mar 7;14(6):573. doi: 10.3390/diagnostics14060573.
7
F-FDG-PET/CT-based deep learning model for fully automated prediction of pathological grading for pancreatic ductal adenocarcinoma before surgery.基于F-FDG-PET/CT的深度学习模型用于术前全自动预测胰腺导管腺癌的病理分级
EJNMMI Res. 2023 May 25;13(1):49. doi: 10.1186/s13550-023-00985-4.
8
PET/MRI for evaluation of patients with pancreatic cancer.正电子发射断层扫描/磁共振成像(PET/MRI)用于胰腺癌患者的评估。
Abdom Radiol (NY). 2023 Dec;48(12):3601-3609. doi: 10.1007/s00261-023-03943-9. Epub 2023 May 16.
9
The progress of PET/MRI in clinical management of patients with pancreatic malignant lesions.PET/MRI在胰腺恶性病变患者临床管理中的进展
Front Oncol. 2023 Apr 28;13:920896. doi: 10.3389/fonc.2023.920896. eCollection 2023.
10
Imaging glucose metabolism to reveal tumor progression.成像葡萄糖代谢以揭示肿瘤进展。
Front Physiol. 2023 Feb 2;14:1103354. doi: 10.3389/fphys.2023.1103354. eCollection 2023.